Alpha 2.0
Login Register
» Articles » PMID: 39959675

Direct Reciprocal Interaction Between Platelet Count and HBeAg Status in HBsAg-positive Pregnant Women

Overview
Journal Acta Inform Med
Specialty General Medicine
Date 2025 Feb 17
PMID 39959675
Authors
Nguyen Tien Dung
Bui Thi Thu Huong
Ho Cam Tu
Hoang Thi Ngoc Tram
Affiliations
Soon will be listed here.
Abstract

Background: Chronic hepatitis B virus (HBV) infection is a global health issue with a significant impact on pregnant women, mainly due to the interplay between liver function and hematological changes. The liver plays a key role in erythropoiesis and systemic hemostasis. In HBeAg-positive pregnant women, platelet dynamics may be uniquely influenced by the interaction of HBV, immune modulation in pregnancy, and liver function. This area remains underexplored.

Objective: Our study aimed to analyze the interaction between HbeAg status with others preclinical factors by using the matrix correlation and multidimensional statistics methods.

Methods: We used SEM (Structural Equation Modeling) to demonstrate and quantify the direct reciprocal interaction between platelet count and HBeAg status in HBsAg-positive pregnant women.

Results: We found the quantity of platelet, with the optimal threshold is 201x10^3cells/ml, directly relates with HBeAg status (R =0.24) and negatively correlates with ratio of AST on ALT (R=-0.139). In case of HbeAg positive, the risk ratio having a high quantity of platelet (>201x103cells/ml) and high AST/ALT ratio (>1.42) is 2.16[1.23,3.80] (p<0.05). SEM model shows that platelet count has a direct impact on HBeAg (p<0.05, Coefficient =0.24) and indirectly through the AST/ALT ratio. This impact is greater than the direct impact from HBeAg on platelet count (p < 0.05, coefficient = 0.23).

Conclusion: Research results show a complex relationship between platelet count, AST/ALT ratio and HBeAg in patients with chronic hepatitis B. The direct interaction between platelet count, HBeAg status, and AST/ALT ratio suggests intriguing complex immuno-biochemical responses to chronic hepatitis B virus (HBV) infection.

References
1.
Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View
2.
Terrault N, Bzowej N, Chang K, Hwang J, Jonas M, Murad M . AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2015; 63(1):261-83. PMC: 5987259. DOI: 10.1002/hep.28156. View
3.
Moosavy S, Eftekhar E, Davoodian P, Nejatizadeh A, Shadman M, Zare S . AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran. BMC Gastroenterol. 2023; 23(1):145. PMC: 10173614. DOI: 10.1186/s12876-023-02780-w. View
4.
Wai C, Cheng C, Wee A, Dan Y, Chan E, Chua W . Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int. 2006; 26(6):666-72. DOI: 10.1111/j.1478-3231.2006.01287.x. View
5.
Yang Y, Wang L, Yan L, Zhang L, Zhou W, Chen Q . Platelet count is closely associated with the severity of liver injury in patients with chronic hepatitis B virus infection: A cross-sectional study. Exp Ther Med. 2020; 20(1):243-250. PMC: 7296297. DOI: 10.3892/etm.2020.8703. View